In the past year, Intuitive Surgical has seen procedure growth in the US slow, particularly in bariatric surgeries influenced by rising GLP-1 use, even as its operating margin widened for three consecutive years and management raised its 2026 non-GAAP gross margin forecast while continuing to fund R&D.
An interesting tension is emerging as hospital capital budget constraints and shifting procedure mix weigh on growth expectations, even while analysts remain optimistic and management prioritizes long-term utilization and broader adoption of its robotic systems.
We'll now examine how slowing US procedure growth tied to deferrable and bariatric cases may reshape Intuitive Surgical's broader investment narrative.
Find 48 companies with promising cash flow potential yet trading below their fair value.
To own Intuitive Surgical, you need to believe robotic-assisted surgery remains a core part of hospital care, with procedure growth and system utilization driving returns on its premium valuation. The latest news about slower US procedures, especially bariatric cases affected by GLP-1 use, directly touches the key near term catalyst: sustaining procedure growth. It also highlights the biggest current risk, that hospital budget pressure and shifting procedure mix could dampen system placements and utilization. The stock's recent pullback reflects these concerns, but does not appear to fundamentally alter the long term adoption thesis yet.
Against this backdrop, management's decision to raise its 2026 non GAAP gross margin outlook while continuing to fund R&D looks especially important. It signals confidence in maintaining healthy unit economics even as mix and capital budgets come under pressure, and ties back to the catalyst of growing high margin recurring revenue from instruments and services. If Intuitive can sustain margins while expanding indications and utilization, it could blunt some of the financial impact from slower US bariatric volumes and capital spending constraints.
But despite this, hospital budgets and payer scrutiny remain a risk investors should be aware of, because...
Read the full narrative on Intuitive Surgical (it's free!)
Intuitive Surgical's narrative projects $15.6 billion revenue and $4.7 billion earnings by 2029. This requires 12.1% yearly revenue growth and about a $1.6 billion earnings increase from $3.1 billion today.
Uncover how Intuitive Surgical's forecasts yield a $501.73 fair value, a 32% upside to its current price.
While consensus now weighs US bariatric softness and budgets, the most optimistic analysts once saw US$17.2 billion revenue and US$4.9 billion earnings by 2029, which shows just how differently you and others might view procedure risk and GLP 1 headwinds as new information emerges.
Explore 11 other fair value estimates on Intuitive Surgical - why the stock might be worth as much as 66% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ISRG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]